66 research outputs found
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of COPD in Patients with Moderate Airflow Obstruction
Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of Chronic Obstructive Pulmonary Disease
Introduction:
Chronic Obstructive Pulmonary Disease (COPD) is underdiagnosed, and measurement of spirometry
alongside low-dose computed tomography (LDCT) screening for lung cancer is one strategy to
increase earlier diagnosis of this disease. //
Methods:
Ever-smokers at high risk of lung cancer were invited to the Yorkshire Lung Screening Trial for a Lung
Health Check (LHC) comprising LDCT screening, pre-bronchodilator spirometry and smoking
cessation service. In this cross-sectional study we present data on participant demographics,
respiratory symptoms, lung function, emphysema on imaging and both self-reported and primary
care diagnoses of COPD. Multivariable logistic regression analysis identified factors associated with
possible underdiagnosis and misdiagnosis of COPD in this population, with airflow obstruction (AO)
defined as FEV1/FVC ratio <0.70. //
Results:
Of 3,920 LHC attendees undergoing spirometry, 17% had undiagnosed AO with respiratory
symptoms, representing potentially undiagnosed COPD. Compared to those with a primary care
COPD code, this population had milder symptoms, better lung function, and were more likely to be
current smokers (pâ€0.001 for all comparisons). Of 836 attendees with a primary care COPD code
who underwent spirometry, 19% did not have AO, potentially representing misdiagnosed COPD,
although symptom burden was high. //
Discussion:
Spirometry offered alongside LDCT screening can potentially identify cases of undiagnosed and
misdiagnosed COPD. Future research should assess the downstream impact of these findings to
determine if any meaningful changes to treatment and outcomes occurs, and also to assess the
impact on co-delivering spirometry on other parameters of LDCT screening performance such as
participation and adherence. Additionally, work is needed to better understand the aetiology of
respiratory symptoms in those with misdiagnosed COPD, to ensure this highly symptomatic group
receive evidence-based interventions
Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease A Systematic Review
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
Background: Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-effective benefits. A sub-study will risk stratify participants for heart failure to investigate whether any beneficial effect of bisoprolol is restricted to those with unrecognised heart disease. Methods: BICS is a pragmatic randomised parallel group double-blind placebo-controlled trial conducted in UK primary and secondary care sites. The major inclusion criteria are an established predominant respiratory diagnosis of COPD (post-bronchodilator FEV1 < 80% predicted, FEV1/FVC < 0.7), a self-reported history of â„ 2 exacerbations requiring treatment with antibiotics and/or oral corticosteroids in a 12-month period since March 2019, age â„ 40 years and a smoking history â„ 10 pack years. A computerised randomisation system will allocate 1574 participants with equal probability to intervention or control groups, stratified by centre and recruitment in primary/secondary care. The intervention is bisoprolol (1.25 mg tablets) or identical placebo. The dose of bisoprolol/placebo is titrated up to a maximum of 4 tablets a day (5 mg bisoprolol) over 4â7 weeks depending on tolerance to up-dosing of bisoprolol/placeboâthese titration assessments are completed by telephone or video call. Participants complete the remainder of the 52-week treatment period on the final titrated dose (1, 2, 3, 4 tablets) and during that time are followed up at 26 and 52 weeks by telephone or video call. The primary outcome is the total number of participant reported COPD exacerbations requiring oral corticosteroids and/or antibiotics during the 52-week treatment period. A sub-study will risk stratify participants for heart failure by echocardiography and measurement of blood biomarkers. Discussion: The demonstration that bisoprolol reduces the incidence of exacerbations would be relevant not only to patients and clinicians but also to healthcare providers, in the UK and globally. Trial registration: Current controlled trials ISRCTN10497306. Registered on 16 August 201
Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility
Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects
The heritability of chronic obstructive pulmonary disease (COPD) cannot be fully explained by recognized genetic risk factors identified as achieving genome-wide significance. In addition, the combined contribution of genetic variation to COPD risk has not been fully explored. We sought to determine: (1) whether studies of variants from previous studies of COPD or lung function in a larger sample could identify additional associated variants, particularly for severe COPD; and (2) the impact of genetic risk scores on COPD. We genotyped 3,346 single-nucleotide polymorphisms (SNPs) in 2,588 cases (1,803 severe COPD) and 1,782 control subjects from four cohorts, and performed association testing with COPD, combining these results with existing genotyping data from 6,633 cases (3,497 severe COPD) and 5,704 control subjects. In addition, we developed genetic risk scores from SNPs associated with lung function and COPD and tested their discriminatory power for COPD-related measures. We identified significant associations between SNPs near PPIC (P = 1.28 X 10-8) and PPP4R4/SERPINA1 (P = 1.0131028) and severe COPD; the latter association may be driven by recognized variants in SERPINA1. Genetic risk scores based on SNPs previously associated with COPD and lung function had a modest ability to discriminate COPD (area under the curve, ~0.6), and accounted for a mean 0.9â1.9% lower forced expiratory volume in 1 second percent predicted for each additional risk allele. In a large genetic association analysis, we identified associations with severe COPD near PPIC and SERPINA1. A risk score based on combining genetic variants had modest, but significant, effects on risk of COPD and lung function
Susceptibility to chronic mucus hypersecretion, a genome wide association study
Background: Chronic mucus hypersecretion (CMH) is associated with an increased frequency of respiratory infections, excess lung function decline, and increased hospitalisation and mortality rates in the general population. It is associated with smoking, but it is unknown why only a minority of smokers develops CMH. A plausible explanation for this phenomenon is a predisposing genetic constitution. Therefore, we performed a genome wide association (GWA) study of CMH in Caucasian populations.Methods: GWA analysis was performed in the NELSON-study using the Illumina 610 array, followed by replication and metaanalysis in 11 additional cohorts. In total 2,704 subjects with, and 7,624 subjects without CMH were included, all current or former heavy smokers (>= 20 pack-years). Additional studies were performed to test the functional relevance of the most significant single nucleotide polymorphism (SNP).Results: A strong association with CMH, consistent across all cohorts, was observed with rs6577641 (p = 4.25610(-6), OR = 1.17), located in intron 9 of the special AT-rich sequence-binding protein 1 locus (SATB1) on chromosome 3. The risk allele (G) was associated with higher mRNA expression of SATB1 (4.3610 29) in lung tissue. Presence of CMH was associated with increased SATB1 mRNA expression in bronchial biopsies from COPD patients. SATB1 expression was induced during differentiation of primary human bronchial epithelial cells in culture.Conclusions: Our findings, that SNP rs6577641 is associated with CMH in multiple cohorts and is a cis-eQTL for SATB1, together with our additional observation that SATB1 expression increases during epithelial differentiation provide suggestive evidence that SATB1 is a gene that affects CMH.</p
Bisoprolol in Patients With COPD at High Risk of Exacerbation
Importance: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that ÎČ-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial reported that metoprolol did not reduce COPD exacerbations and increased COPD exacerbations requiring hospital admission.
Objective: To test whether bisoprolol decreased COPD exacerbations in people with COPD at high risk of exacerbations.
Design, Setting and Participants: The Bisoprolol in COPD Study (BICS) was a double-blind placebo-controlled randomized clinical trial conducted in 76 UK sites (45 primary care clinics and 31 secondary clinics). Patients with COPD who had at least moderate airflow obstruction on spirometry (FEV1/FVC <0.7, FEV1 <80% predicted) and â„2 COPD exacerbations treated with oral corticosteroids and/or antibiotics in the prior 12 months were enrolled from October 17, 2018, to May 31, 2022. Follow-up concluded on April 18, 2023.
Interventions: Patients were randomly assigned to bisoprolol (n=261) or placebo (n=258). Bisoprolol was started at 1.25 mg orally daily and was titrated as tolerated over 4 sessions to a maximum dose of 5 mg/d using a standardized protocol.
Main outcomes and Measures: The primary clinical outcome was the number of patient reported COPD exacerbations treated with oral corticosteroids and/or antibiotics over the 1- year treatment period. Safety outcomes included serious adverse events and adverse reactions.
Results: Although the trial planned to enroll 1574 patients, recruitment was suspended from March, 16, 2020, to July 31, 2021, due to the COVID-19 pandemic. Two patients in each group were excluded post randomization. Among the 515 patients (mean age, 68 years; men, 274 [53%]; mean FEV1, 50.1%, primary outcome data were available for 514 (99.8%) and 371 (72%) remained on study drug. The primary outcome of patient-reported COPD exacerbations treated with oral corticosteroids and/or antibiotics was 526 in bisoprolol group, with a mean exacerbation rate of 2.03/year vs 513 exacerbations in the placebo group with a mean exacerbation rate of 2.01/year, adjusted incidence rate ratio (IRR) [95% CI, 0.97 (0.84, 1.13), p=0.72]. Serious adverse events occurred in 37 (14.5%) of the bisoprolol group vs 36 (14.3%) in the placebo group, [relative risk 1.01 95% CI, 0.62, 1.66), p=0.96].
Conclusions and Relevance: Among people with COPD at high risk of exacerbation, treatment with bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids and/or antibiotics
VII Scandinavian Copd Research Symposium, Holmenkollen, Oslo 18th-19th November 2016
Peer reviewe
Susceptibility to chronic mucus hypersecretion, a genome wide association study
Background: Chronic mucus hypersecretion (CMH) is associated with an increased frequency of respiratory infections, excess lung function decline, and increased hospitalisation and mortality rates in the general population. It is associated with smoking, but it is unknown why only a minority of smokers develops CMH. A plausible explanation for this phenomenon is a predisposing genetic constitution. Therefore, we performed a genome wide association (GWA) study of CMH in Caucasian populations. Methods: GWA analysis was performed in the NELSON-study using the Illumina 610 array, followed by replication and meta-analysis in 11 additional cohorts. In total 2,704 subjects with, and 7,624 subjects without CMH were included, all current or former heavy smokers (â„20 pack-years). Additional studies were performed to test the functional relevance of the most significant single nucleotide polymorphism (SNP). Results: A strong association with CMH, consistent across all cohorts, was observed with rs6577641 (p = 4.25x10-6, OR = 1.17), located in intron 9 of the special AT-rich sequence-binding protein 1 locus (SATB1) on chromosome 3. The risk allele (G) was associated with higher mRNA expression of SATB1 (4.3x10 -9) in lung tissue. Presence of CMH was associated with increased SATB1 mRNA expression in bronchial biopsies from COPD patients. SATB1 expression was induced during differentiation of primary human bronchial epithelial cells in culture. Conclusions: Our findings, that SNP rs6577641 is associated with CMH in multiple cohorts and is a cis-eQTL for SATB1, together with our additional observation that SATB1 expression increases during epithelial differentiation provide suggestive evidence that SATB1 is a gene that affects CMH
- âŠ